You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

idelalisib

( eye del'' a lis' ib )
Funding:
Exceptional Access Program
  • idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria
Other Name(s): Zydelig™
Appearance: tablet

You might also be interested in